Vg Life Sciences Financials
This page shows Vg Life Sciences (VGLS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Vg Life Sciences passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Vg Life Sciences generates $0.31 in operating cash flow (-$1.9M OCF vs -$6.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Vg Life Sciences earns $-1.5 in operating income for every $1 of interest expense (-$4.1M vs $2.8M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Vg Life Sciences generated $0 in revenue in fiscal year 2014.
Vg Life Sciences's EBITDA was -$4.1M in fiscal year 2014, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 6.0% from the prior year.
Vg Life Sciences reported -$6.2M in net income in fiscal year 2014. This represents an increase of 16.6% from the prior year.
Cash & Balance Sheet
Vg Life Sciences generated -$1.9M in free cash flow in fiscal year 2014, representing cash available after capex. This represents a decrease of 84.0% from the prior year.
Vg Life Sciences held $34K in cash against $0 in long-term debt as of fiscal year 2014.
Vg Life Sciences had 46M shares outstanding in fiscal year 2014. This represents an increase of 164.7% from the prior year.
Margins & Returns
Capital Allocation
Vg Life Sciences invested $866K in research and development in fiscal year 2014. This represents an increase of 7.1% from the prior year.
Vg Life Sciences invested $0 in capex in fiscal year 2014, funding long-term assets and infrastructure.
VGLS Income Statement
| Metric | Q3'15 | Q2'15 | Q1'15 | Q4'14 | Q3'14 | Q2'14 | Q1'14 | Q4'13 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $140K-13.9% | $163K+2.0% | $160K | N/A | $340K+51.5% | $224K-45.5% | $412K | N/A |
| SG&A Expenses | $119K-6.6% | $127K-8.2% | $138K | N/A | $65K-78.2% | $296K-19.9% | $370K | N/A |
| Operating Income | -$644K+12.8% | -$739K+7.8% | -$801K | N/A | -$799K+30.6% | -$1.2M+30.3% | -$1.7M | N/A |
| Interest Expense | $250K-42.1% | $432K-39.6% | $715K | N/A | $688K+24.1% | $554K-35.0% | $852K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$1.0M+27.5% | -$1.4M+4.4% | -$1.5M | N/A | -$1.1M+46.8% | -$2.0M+26.1% | -$2.7M | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
VGLS Balance Sheet
| Metric | Q3'15 | Q2'15 | Q1'15 | Q4'14 | Q3'14 | Q2'14 | Q1'14 | Q4'13 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.1M+0.1% | $1.1M-4.5% | $1.2M-11.7% | $1.3M+16.3% | $1.1M | N/A | N/A | $1.9M |
| Current Assets | $40K+2.3% | $39K-57.2% | $92K-62.6% | $246K+307.3% | $60K | N/A | N/A | $789K |
| Cash & Equivalents | $23K+428.7% | $4K-85.6% | $30K-11.5% | $34K-36.9% | $54K+63.9% | $33K-77.9% | $149K-79.2% | $714K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $5.5M-8.3% | $6.0M+1.1% | $5.9M+1.1% | $5.8M-7.6% | $6.3M | N/A | N/A | $6.3M |
| Current Liabilities | $5.5M-8.3% | $6.0M+1.1% | $5.9M+1.1% | $5.8M-7.6% | $6.3M | N/A | N/A | $6.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$4.3M+10.3% | -$4.8M-2.5% | -$4.7M-4.9% | -$4.5M+12.8% | -$5.2M | N/A | N/A | -$4.5M |
| Retained Earnings | -$109.8M-0.9% | -$108.8M-1.3% | -$107.4M-1.4% | -$106.0M-0.4% | -$105.5M | N/A | N/A | -$99.8M |
VGLS Cash Flow Statement
| Metric | Q3'15 | Q2'15 | Q1'15 | Q4'14 | Q3'14 | Q2'14 | Q1'14 | Q4'13 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$48K+79.7% | -$238K-43.9% | -$165K+59.5% | -$407K+13.0% | -$468K-51.6% | -$309K+57.4% | -$725K-34.3% | -$540K |
| Capital Expenditures | N/A | N/A | N/A | $0 | N/A | N/A | N/A | $0 |
| Free Cash Flow | N/A | N/A | N/A | -$407K | N/A | N/A | N/A | -$540K |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
VGLS Financial Ratios
| Metric | Q3'15 | Q2'15 | Q1'15 | Q4'14 | Q3'14 | Q2'14 | Q1'14 | Q4'13 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -90.7%+34.6pp | -125.3%-0.2pp | -125.1% | N/A | -93.5% | N/A | N/A | N/A |
| Current Ratio | 0.010.0 | 0.010.0 | 0.02-0.0 | 0.04+0.0 | 0.01 | N/A | N/A | 0.12 |
| Debt-to-Equity | -1.26-0.0 | -1.23+0.0 | -1.25+0.0 | -1.29-0.1 | -1.22 | N/A | N/A | -1.42 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$4.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Frequently Asked Questions
What is Vg Life Sciences's annual revenue?
Vg Life Sciences (VGLS) reported $0 in total revenue for fiscal year 2014. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Vg Life Sciences profitable?
No, Vg Life Sciences (VGLS) reported a net income of -$6.2M in fiscal year 2014.
What is Vg Life Sciences's EBITDA?
Vg Life Sciences (VGLS) had EBITDA of -$4.1M in fiscal year 2014, measuring earnings before interest, taxes, depreciation, and amortization.
What is Vg Life Sciences's free cash flow?
Vg Life Sciences (VGLS) generated -$1.9M in free cash flow during fiscal year 2014. This represents a -84.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Vg Life Sciences's operating cash flow?
Vg Life Sciences (VGLS) generated -$1.9M in operating cash flow during fiscal year 2014, representing cash generated from core business activities.
What are Vg Life Sciences's total assets?
Vg Life Sciences (VGLS) had $1.3M in total assets as of fiscal year 2014, including both current and long-term assets.
What are Vg Life Sciences's capital expenditures?
Vg Life Sciences (VGLS) invested $0 in capital expenditures during fiscal year 2014, funding long-term assets and infrastructure.
How much does Vg Life Sciences spend on research and development?
Vg Life Sciences (VGLS) invested $866K in research and development during fiscal year 2014.
What is Vg Life Sciences's current ratio?
Vg Life Sciences (VGLS) had a current ratio of 0.04 as of fiscal year 2014, which is below 1.0, which may suggest potential liquidity concerns.
What is Vg Life Sciences's debt-to-equity ratio?
Vg Life Sciences (VGLS) had a debt-to-equity ratio of -1.29 as of fiscal year 2014, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Vg Life Sciences's return on assets (ROA)?
Vg Life Sciences (VGLS) had a return on assets of -467.8% for fiscal year 2014, measuring how efficiently the company uses its assets to generate profit.
What is Vg Life Sciences's cash runway?
Based on fiscal year 2014 data, Vg Life Sciences (VGLS) had $34K in cash against an annual operating cash burn of $1.9M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Vg Life Sciences's debt-to-equity ratio negative or unusual?
Vg Life Sciences (VGLS) has negative shareholder equity of -$4.5M as of fiscal year 2014, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Vg Life Sciences's Piotroski F-Score?
Vg Life Sciences (VGLS) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Vg Life Sciences's earnings high quality?
Vg Life Sciences (VGLS) has an earnings quality ratio of 0.31x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Vg Life Sciences cover its interest payments?
Vg Life Sciences (VGLS) has an interest coverage ratio of -1.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.